Companies › Impax Laboratories
1 active drug program in 3 registered trials: 3 Phase 4; Neurology, Psychiatry.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Carbidopa DOPA decarboxylase inhibitor | DDC | Phase 4 | Parkinson Disease; Anhedonia | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06765668 | Carbidopa | Phase 4 | Parkinson Disease | Neurology | Nov 2025 |
| NCT06075771 | Carbidopa | Phase 4 | Anhedonia | Psychiatry | Jan 2027 |
| NCT06013956 | Carbidopa | Phase 4 | Parkinson Disease | Neurology | Jun 2028 |
Sichuan Jishengtang Pharmaceutical Rapport Therapeutics Lipocine Intra-Cellular Therapies Upsher-Smith Laboratories
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.